Document Detail


Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma.
MedLine Citation:
PMID:  11911308     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Oesophageal carcinoma is one of the more aggressive cancers and the patients usually seek medical attention only when the disease is already advanced. Therefore it is important to have a tool, which is simple and fast, to measure and to predict the prognosis for these patients. Mutations in the p53 gene are among the most common genetic abnormalities in oesophageal carcinoma. The present study is the first study, to our knowledge, in which the relationship between the presence of p53 autoantibodies in the serum and survival has been investigated in patients with oesophageal carcinoma. PATIENTS AND METHODS: Serum from patients with oesophagal carcinoma was collected between 1996 and 1999 at the Department of Oncology, Uppsala University Hospital, Sweden. The serum samples were analysed for the presence of p53 autoantibodies using a sandwich ELISA. RESULTS: In a multivariate analysis, the presence of p53 autoantibodies was associated with decreased survival (p=0.047). Patients with extensive disease had a poor prognosis and time to death was decreased in these patients (p=0.000022). The one-year survival was 0% for these patients if they had p53 autoantibodies compared to 36% for patients with no p53 autoantibodies and extensive disease. CONCLUSION: We conclude that the presence of serum p53 autoantibodies is associated with decreased survival for patients with oesophageal carcinoma.
Authors:
A S Bergqvist; M Bergqvist; D Brattstrom; P Hesselius; A Larsson; O Brodin; G Wagenius
Related Documents :
20931428 - Is the prevalence of intestinal metaplasia at the squamocolumnar junction different in ...
7489928 - Reflux related symptoms in patients with normal oesophageal exposure to acid.
20105278 - Effect of proximal gastric volume on hiatal hernia.
20600028 - Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms.
21881468 - Dbs candidates that fall short on a levodopa challenge test: alternative and important ...
17922748 - Challenges and limitations of maintenance hemodialysis in urban south india.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  21     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2001 Nov-Dec
Date Detail:
Created Date:  2002-03-25     Completed Date:  2002-04-19     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  4141-5     Citation Subset:  IM    
Affiliation:
Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / immunology
Autoantibodies / blood*
Carcinoma, Adenosquamous / immunology
Carcinoma, Squamous Cell / immunology
Esophageal Neoplasms / immunology*
Female
Humans
Male
Prognosis
Prospective Studies
Survival Rate
Tumor Markers, Biological / blood,  immunology
Tumor Suppressor Protein p53 / immunology*
Chemical
Reg. No./Substance:
0/Autoantibodies; 0/Tumor Markers, Biological; 0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanc...
Next Document:  In vitro chemosensitivity of human soft tissue sarcoma.